Molecular Medicine and Gene Therapy

Faculty of Medicine | Lund University

Menu

Molecular Medicine and Gene Therapy

bmc view banner

The Division of Molecular Medicine and Gene Therapy is located at the Biomedical Center (BMC), Lund University, Sweden. Established as a joint venture between the Medical Faculty at Lund University and the Hematology Clinic at Lund University Hospital, our mission is to translate basic science to clinical applications.

Our research focuses on hematopoiesis, the continuous and dynamic process of blood cell formation. The laboratory consists of eight closely collaborating research groups that all share a common interest in investigating the properties of blood stem cells to eventually understand and treat hematological disorders.

Five of our researchers belong to the Hemato-Linné Excellence Linnaeus Research Environment funded by The Swedish Research Council and Lund University. Several of the groups are engaged in StemTherapy, a Strategic Research Area for Stem Cells and Regenerative Medicine that is also supported by The Swedish Research Council.

News

dissertation roman galeev
From left: Urban Gullberg, Johanna Ungerstedt, Anna Hagström, Roman Galeev, Johannes Zuber, Jonas Larsson. Photo credit: Claire McKay

On September 13, 2018, Roman Galeev successfully defended his thesis entitled "Identification of intrinsic regulators in normal and malignant human hematopoiesis - An RNA-interference approach".

Faculty opponent was Professor Johannes Zuber, Medical University of Vienna, Austria. Main supervisor for Roman's PhD studies was Professor Jonas Larsson.

Congratulations Roman!

roman galeev

Dissertation Roman Galeev

Division of Molecular Medicine & Gene Therapy, Department of Laboratory Medicine

Title: "Identification of intrinsic regulators in normal and malignant human hematopoiesis - An RNA-interference approach"

Date: September 13, 2018 at 9 am

Place: Lux Aula övre, LUX

Opponent: Professor Johannes Zuber, Medical University of Vienna, Austria

Main supervisor: Professor Jonas Larsson

Welcome!

mehrnaz safaee

Congratulations Mehrnaz Safaee Talkhoncheh, Aurélie Baudet and Jonas Larsson on the publication of your work "Transient Inhibition Of NF-ΚB Signaling Enhances Ex Vivo Propagation Of Human Hematopoietic Stem Cells" in Haematologica.

In this study, the authors have shown that chemical inhibition of the NF-kB signaling pathway facilitates the propagation of human hematopoietic stem- and progenitor cells in culture.

This work will also lay the foundation for Mehrnaz' doctoral dissertation which is scheduled for November 2018.

Congratulations to all authors!

charlotta boeiers

Congratulations Charlotta Böiers and Tariq Enver on the publication of your work "A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1" in Developmental Cell.

In this collaboration between Lund University and University College London, the authors have discovered that the commonest type of childhood acute leukaemia may start in the early foetus as a result of a developmental susceptibility in developing immune cells.

Further reading

Press release from Lund University

Press release from University College London

johan richter
Johan Richter, Lunds univeristet och Skånes universitetssjukhus.

Congratulations to Johan Richter and his colleagues from the European Stop Kinase Inhibitor (EURO-SKI) trial on the publication of your work "Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial" in The Lancet Oncology.

In this major collaborative European effort, the authors enrolled more than 800 patients with chronic myeloid leukemia (CML) at 61 European centers in 11 countries with the aim to estimate the persistence of molecular remission in these patients after stopping Tyrosine Kinase Inhibitor (TKI) treatment.

- We hope that the results from this study can form the basis for new treatment guidelines and help move the concept of stopping TKI-therapy in CML patients with a deep molecular response into standard clinical practice, says Johan Richter, Professor at the Division of Molecular Medicine and Gene Therapy and Senior Consultant in Hematology at Skåne University Hospital.

Site overview